Dyslipidemia in Type 2 Diabetes and the Effects of Thiazolidinediones

Endocrinologist

Volumn 13, Issue 6, 2003, Pages 496-504

  Bell, David S H ^a,b  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b Boshell Diabetes Research Building ^*  (United States)

Author keywords

Atherosclerosis; Insulin resistance; Thiazolidinediones

Indexed keywords

ANTIDIABETIC AGENT; ATORVASTATIN; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MEVINOLIN; NICOTINIC ACID; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE;

ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART PROTECTION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0344851801     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000098612.88907.4b     Document Type: Review

References (107)

1. Alberti KGMM. Treating type 2 diabetes - today's targets, tomorrow's goals. Diabetes Obes Metabol. 2001;3(suppl 1):S3-S10.
2. Wilson PW, Kannel WB, Anderson KM. Lipids, glucose intolerance and vascular disease: the Framingham Study. Monogr Atheroscler. 1985;13:1-11.
3. Laakso M. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus. Ann Med. 1996;28:341-345.
4. Syvanne M, Ahola M, Lahdenpera S, et al. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res. 1995;36:573-582.
5. Verges B, Brun JM, Vaillant G, et al. Influence of obesity and hypertriglyceridaemia on the low HDL2-cholesterol level and on its relationship with prevalence of atherosclerosis in type 2 diabetes. Diabetes Metab. 1992;18:289-297.
6. Bakogianni MC, Kalofoutis CA, Skenderi KI, et al. Clinical evaluation of plasma high-density lipoprotein subfractions (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease. J Diabetes Complications. 2001;15:265-269.
7. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81:7B-12B.
8. Miller M. Differentiating the effects of raising low levels of high-density lipoprotein cholesterol versus lowering normal triglycerides: further insights from the veterans affairs high-density lipoprotein intervention trial. Am J Cardiol. 2000;86(suppl 1):23-27.
9. Selby JV, Austin MA, Newman B, et al. LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation. 1993;88:381-387.
10. Tan KC, Shiu SW, Chu BY. Roles of hepatic lipase and cholesteryl ester transfer protein in determining low density lipoprotein subfraction distribution in Chinese patients with non-insulin-dependent diabetes mellitus. Atherosclerosis. 1999;145:273-278.
11. Gray RS, Robbins DC, Wang W, et al. Relation of LDL size to the insulin resistance syndrome and coronary heart disease in American Indians. The Strong Heart Study. Arterioscler Thromb Vasc Biol. 1997;17:2713-2720.
12. Haffner SM, Mykkanen L, Robbins D, et al. A preponderance of small dense LDL is associated with specific insulin, proinsulin and the components of the insulin resistance syndrome in non-diabetic subjects. Diabetologia. 1995;38:1328-1336.
13. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917-1921.
14. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation. 1997;95:69-75.
15. Lamarche B, St. Pierre AC, Ruel IL, et al. A prospective, population-based study of low density lipoprotein particle size as a risk factor for ischemic heart disease in men. Can J Cardiol. 2001;17:859-865.
16. Liu ML, Ylitalo K, Nuotio I, et al. Association between carotid intima-media thickness and low-density lipoprotein size and susceptibility of low-density lipoprotein to oxidation in asymptomatic members of familial combined hyperlipidemia families. Stroke. 2002;33:1255-1260.
17. Landray MJ, Sagar G, Muskin J, et al. Association of atherogenic low-density lipoprotein subfractions with carotid atherosclerosis. QJM. 1998;91:345-351.
18. Chait A, Brazg RL, Tribble DL, et al. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med. 1993;94:350-356.
19. Kondo A, Muranaka Y, Ohta I, et al. Relationship between triglyceride concentrations and LDL size evaluated by malondialdehyde-modified LDL. Clin Chem. 2001;47:893-900.
20. Haffner SM, Agil A, Mykkanen L, et al. Plasma oxidizability in subjects with normal glucose tolerance, impaired glucose tolerance, and NIDDM. Diabetes Care. 1995;18:646-653.
21. Lyons TJ, Li W, Wells-Knecht MC, et al. Toxicity of mildly modified low-density lipoproteins to cultured retinal capillary endothelial cells and pericytes. Diabetes. 1994;43:1090-1095.
22. Quinn MT, Parthasarathy S, Fong LG, et al. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci U S A. 1987;84:2995-2998.
23. Sakai M, Miyazaki A, Hakamata H, et al. Lysophosphatidylcholine potentiates the mitogenic activity of modified LDL for human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol. 1996;16:600-605.
24. Hoff HF, O'Neil J, Chisolm GM III, et al. Modification of low density lipoprotein with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis. 1989;9:538-549.
25. Bucala R, Cerami A, Vlassara H. Advanced glycosylation end products in diabetic complications: biochemical basis and prospects for therapeutic intervention. Diabetes Reviews. 1995;3:258-268.
26. Cook CB, Erdman DM, Ryan GJ, et al. The pattern of dyslipidemia among urban African-Americans with type 2 diabetes. Diabetes Care. 2000;23:319-324.
27. Mykkänen L, Kuusisto J, Pyörälä K, et al. Cardiovascular disease risk factors as predictors of type 2 (non-insulin-dependent) diabetes mellitus in elderly subjects. Diabetologia. 1993;36:553-559.
28. Haffner SM, Stem MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;263:2893-2898.
29. Reaven GM. Insulin resistance and human disease: a short history. J Basic Clin Physiol Pharmacol. 1998;9:387-406.
30. Groop LC. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metabol. 1999;1(suppl 1):S1-S7.
31. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol. 1999;84(suppl):28J-32J.
32. Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol. 1997;8:146-153.
33. Sidossis LS, Mittendorfer B, Walser E, et al. Hyperglycemia-induced inhibition of splanchnic fatty acid oxidation increases hepatic triacylglycerol secretion. Am J Physiol. 1998;275:E798-E805.
34. Malmstrom R, Packard CJ, Caslake M, et al. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM. Diabetologia. 1997;40:454-462.
35. Lewis GF, Uffelman KD, Szeto LW, et al. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals. Diabetes. 1993;42:833-842.
36. Thompson GR, Naoumova RP, Watts GF. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J Lipid Res. 1996;37:439-447.
37. Maheux P, Azhar S, Kern PA, et al. Relationship between insulin-mediated glucose disposal and regulation of plasma and adipose tissue lipoprotein lipase. Diabetologia. 1997;40:850-858.
38. Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes. 1996;45(suppl 3):S27-S30.
39. Carr MC, Ayyobi AF, Murdoch SJ, et al. Contribution of hepatic lipase, lipoprotein lipase, and cholesteryl ester transfer protein to LDL and HDL heterogeneity in healthy women. Arterioscler Thromb Vasc Biol. 2002;22:667-673.
40. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
41. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
42. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
43. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
44. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
45. Kelly JJ, Lawson JA, Campbell LV, et al. Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens. 2000;14:567-572.
46. Vanninen E, Uusitupa M, Siitonen O, et al. Habitual physical activity, aerobic capacity and metabolic control in patients with newly-diagnosed type 2 (non-insulin-dependent) diabetes mellitus: effect of 1-year diet and exercise intervention. Diabetologia. 1992;35:340-346.
47. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
48. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86:280-288.
49. Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis. 2001;12:413-423.
50. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther. 2002;4:145-151.
51. Rosenstock J, Einhorn D, Hershon K, et al. Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract. 2002;56:251-257.
52. Jones NP, Mather R, Owen S, et al. Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin. Diabetologia. 2000;43(suppl 1):A192.
53. Sunayama S, Watanabe Y, Ohmura H, et al. Effects of troglitazone on atherogenic lipoprotein phenotype in coronary patients with insulin resistance. Atherosclerosis. 1999;146:187-193.
54. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90:947-952.
55. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.
56. Ovalle F, Bell DS. Effect of thiazolidinediones on high-density lipoprotein subfractions. Eadocr Pract. 2002;8:102-104.
57. Ovalle F, Bell DSH. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocr Pract. [in press].
58. Chilcott J, Tappenden P, Jones ML, et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001;23:1792-1823.
59. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA. 2001;285:1585-1591.
60. Jones T, Jones NP, Sautter M. Addition of rosiglitazone to metformin is effective in obese, insulin-resistant patients with type 2 diabetes. Diabetologia. 2000;43(suppl 1):A191.
61. Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 2002;18:127-134.
62. Boyle PJ, King AB, Olansky L, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther. 2002;24:378-396.
63. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab. 1999;1:165-172.
64. Kumar S, Boulton AJM, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group. Diabetologia. 1996;39:701-709.
65. Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism: Clinical and Experimental. 2002;51:314-317.
66. Brunzell J, Cohen BR, Kreider M, et al. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes. Diabetes. 2001;50(suppl 2):A141.
67. Tack CJ, Smits P, Demacker PN, et al. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects. Diabetes Care. 1998;21:796-799.
68. Zambon A, Hokanson JE, Brown BG, et al. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation. 1999;99:1959-1964.
69. Guan HP, Li Y, Jensen MV, et al. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med. 2002;8:1122-1128.
70. Arner P. Free fatty acids - do they play a central role in type 2 diabetes? Diabetes Obes Metab. 2001;3(suppl 1):11-19.
71. Bell DS, Ovalle F. Long-term efficacy of triple oral therapy for type 2 diabetes mellitus. Endocr Pract. 2002;8:271-275.
72. Finegood DT, Topp B. β-cell deterioration - prospects for reversal or prevention. Diabetes Obes Metab. 2001;3(suppl 1):S20-S27.
73. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 2001;24:710-719.
74. Balletshofer BM, Rittig K, Volk A, et al. Impaired non-esterified fatty acid suppression is associated with endothelial dysfunction in insulin resistant subjects. Horm Metab Res. 2001;33:428-431.
75. Large V, Arner P. Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia. Diabetes Metab. 1998;24:409-418.
76. Banerji M, Lebovitz HE, Dugbartey M. Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus. Diabetes. 2001;50(suppl 2):A90.
77. Kelley DE, McKolanis TM, Kelley CA. Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus. Diabetes. 2002;51(suppl 2):A35.
78. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). Diabetes. 2000;49(suppl 1):A299.
79. Nakamura T, Funahashi T, Yamashita S, et al. Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation - double-blind placebo-controlled trial. Diabetes Res Clin Pract. 2001;54:181-190.
80. Richard BC, Asnani S, Desouza C, et al. Is weight gain inevitable with thiazolidinediones? Experience with very low calorie diets [Abstract]. Diabetes. 2002;51(suppl 2):A609.
81. Reynolds L, Konz E, Frederich R, et al. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. Diabetes Obes Metab. 2002;4:270-275.
82. Mosca L, Biviano A. Lipid-lowering therapies in the management of acute coronary syndromes. Curr Cardiol Rep. 2002;4:320-326.
83. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2002;25(suppl 1):S33-S49.
84. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health Syst Pharm. 1995;52:1639-1645.
85. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev. 2002;18(suppl 2):S23-S29.
86. Glazer NB, Cheatham WW. Thiazolidinediones for type 2 diabetes. No evidence exists that pioglitazone induces hepatic cytochrome P450 isoform CYP3A4. BMJ. 2001;322:235-236.
87. Harris RZ, Inglis AML, Miller AK, et al. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics. J Clin Pharmacol. 1999;39:1189-1194.
88. Inglis AM, Miller AK, Culkin KT, et al. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. J Clin Pharmacol. 2001;41:683-690.
89. Bell DSH. Why I initiate treatment with two sensitizers in patients with type 2 diabetes. Endocr Pract. [in press].
90. Keen H. Therapeutic objectives and their practical achievement in type 2 diabetes. J Diabetes Complications. 2000;14:180-184.
91. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
92. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
93. Bakris G, Viberti G, Weston W, et al. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens. [in press].
94. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes. 1997;46:433-439.
95. phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect. Diabetes. 2001;50(suppl 2):A68.
96. Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension. 2000;36:430-435.
97. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-kappaB and stimulation of inhibitor kappaB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab. 2001;86:1306-1312.
98. Albert MA, Ridker PM. The role of C-reactive protein in cardiovascular disease risk. Curr Cardiol Rep. 1999;1:99-104.
99. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002;25:542-549.
100. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor I levels. A possible link between insulin resistance and atherothrombosis. Diabetologia. 1991;34:457-462.
101. Thogersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation. 1998;98:2241-2247.
102. Margaglione M, Di Minno G, Grandone E, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arteriosclerosis and Thrombosis. 1994;14:1741-1745.
103. Sobel BE, Woodcock-Mitchell J, Schneider DJ, et al. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation. 1998;97:2213-2221.
104. Freed M, Fuell D, Menci L, et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes. Diabetologia. 2000;43(suppl 1):A267.
105. Gomez-Perez FJ, Aguilar-Salinas CA, Vazquez-Chavez C, et al. Further insight on the hypoglycemic and nonhypoglycemic effects of troglitazone 400 or 600 mg/d: effects on the very-low-density and high-density lipoprotein particle distribution. Metabolism: Clinical and Experimental. 2002;51:44-51.
106. Li AC, Brown KK, Silvestre MJ, et al. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531.
107. Minamikawa J, Tanaka S, Yamauchi M, et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 1998;83:1818-1820.